Trials / Completed
CompletedNCT04721301
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
LUMINESCENCE-001 Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- University Hospital Heidelberg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.
Detailed description
A study to evaluate the safety, tolerability and feasibility of treatment with Maraviroc, nivolumab and ipilimumab in layers of colon and pancreatic cancer patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Nivolumab plus Ipilimumab plus Maraviroc | In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc |
Timeline
- Start date
- 2017-01-15
- Primary completion
- 2023-03-15
- Completion
- 2023-03-15
- First posted
- 2021-01-22
- Last updated
- 2023-10-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04721301. Inclusion in this directory is not an endorsement.